| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0895-7061(01)02316-0 |
| P698 | PubMed publication ID | 11939619 |
| P50 | author | Peter Timms | Q30506537 |
| P2093 | author name string | Paul Maxwell | |
| Stewart Campbell | |||
| Ann Wright | |||
| Anne Beatrice Dawnay | |||
| Vinajur Srikanthan | |||
| P433 | issue | 3 | |
| P921 | main subject | essential hypertension | Q988405 |
| left ventricular hypertrophy | Q1628627 | ||
| P304 | page(s) | 269-272 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Journal of Clinical Hypertension | Q15762840 |
| P1476 | title | Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy | |
| P478 | volume | 15 |
| Q64071126 | Association of Circulating Tissue Inhibitor of Metalloproteinases-1 and Procollagen Type III Aminoterminal Peptide Levels With Incident Heart Failure and Chronic Kidney Disease |
| Q35582221 | Changes in the myocardial interstitium and contribution to the progression of heart failure |
| Q39204240 | Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension |
| Q43230192 | Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension |
| Q24644869 | Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers |
| Q44692647 | Identification, purification and partial characterization of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in bovine pulmonary artery smooth muscle |
| Q44914311 | Improvement in collagen metabolism after 12 weeks' cardiac resynchronization therapy in patients with ischaemic cardiomyopathy |
| Q39195389 | Increased type I collagen synthesis in victims of sudden cardiac death due to idiopathic myocardial fibrosis |
| Q37023639 | Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study |
| Q37195730 | Matrix metalloproteinases and cardiovascular diseases. |
| Q38121745 | Pacing-induced cardiomyopathy: pathophysiological insights through matrix metalloproteinases |
| Q34138706 | Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction |
| Q35170122 | Regression of left ventricular hypertrophy is a key goal of hypertension management |
| Q37312630 | Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community |
| Q47960038 | Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study |
| Q37899085 | Role of various proteases in cardiac remodeling and progression of heart failure |
| Q38120572 | TIMP-1 polymorphisms in a Chinese Han population with intracerebral hemorrhage |
| Q81791292 | The relationship between pulse wave velocity and indexes of collagen synthesis in hypertensive patients, according to the level of systolic blood pressure |
| Q58946977 | Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure |
| Q37895982 | Tissue inhibitor of metalloproteinases (TIMPs) in heart failure |
Search more.